Longitudinal Effect of Eteplirsen Versus Historical Control on Ambulation in Duchenne Muscular Dystrophy

Overview

Journal Ann Neurol

Specialty Neurology

Date 2015 Nov 18

PMID 26573217

Citations 250

Authors

Jerry R Mendell

Nathalie Goemans

Linda P Lowes

Lindsay N Alfano

Katherine Berry

James Shao

Edward M Kaye

Eugenio Mercuri

Affiliations

Soon will be listed here.

Abstract

Objective: To continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three-year progression of eteplirsen-treated patients was compared to matched historical controls (HC).

Methods: Ambulatory DMD patients who were ≥7 years old and amenable to exon 51 skipping were randomized to eteplirsen (30/50mg/kg) or placebo for 24 weeks. Thereafter, all received eteplirsen on an open-label basis. The primary functional assessment in this study was the 6-Minute Walk Test (6MWT). Respiratory muscle function was assessed by pulmonary function testing (PFT). Longitudinal natural history data were used for comparative analysis of 6MWT performance at baseline and months 12, 24, and 36. Patients were matched to the eteplirsen group based on age, corticosteroid use, and genotype.

Results: At 36 months, eteplirsen-treated patients (n = 12) demonstrated a statistically significant advantage of 151m (p < 0.01) on 6MWT and experienced a lower incidence of loss of ambulation in comparison to matched HC (n = 13) amenable to exon 51 skipping. PFT results remained relatively stable in eteplirsen-treated patients. Eteplirsen was well tolerated. Analysis of HC confirmed the previously observed change in disease trajectory at age 7 years, and more severe progression was observed in patients with mutations amenable to exon skipping than in those not amenable. The subset of patients amenable to exon 51 skipping showed a more severe disease course than those amenable to any exon skipping.

Interpretation: Over 3 years of follow-up, eteplirsen-treated patients showed a slower rate of decline in ambulation assessed by 6MWT compared to untreated matched HC.

Citing Articles

Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1.

Saini S, Gadet J, Freeman G, Chiocca E, Mineo M J Neurooncol. 2025; .

PMID: 40035950 DOI: 10.1007/s11060-025-04978-2.

Association of Gene Variant Classes With Motor Outcomes in a Drug Registration Clinical Trial Setting.

Fang Y, Dang U, Illei K, Clemens P, Hoffman E Neurol Genet. 2025; 11(2):e200251.

PMID: 40017558 PMC: 11867578. DOI: 10.1212/NXG.0000000000200251.

Integrating Machine Learning-Based Approaches into the Design of ASO Therapies.

Leckie J, Yokota T Genes (Basel). 2025; 16(2).

PMID: 40004514 PMC: 11855077. DOI: 10.3390/genes16020185.

Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications.

Wu Y, Chen J, Jong Y J Biomed Sci. 2025; 32(1):30.

PMID: 39985020 PMC: 11844187. DOI: 10.1186/s12929-025-01123-z.

Antisense oligonucleotide-mediated TRA2β poison exon inclusion induces the expression of a lncRNA with anti-tumor effects.

Leclair N, Brugiolo M, Park S, Devoucoux M, Urbanski L, Angarola B Nat Commun. 2025; 16(1):1670.

PMID: 39955311 PMC: 11829967. DOI: 10.1038/s41467-025-56913-8.

References

Goemans N, Klingels K, Van den Hauwe M, Boons S, Verstraete L, Peeters C . Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years. PLoS One. 2014; 8(12):e84120. PMC: 3877199. DOI: 10.1371/journal.pone.0084120. View

Sazani P, Van Ness K, Weller D, Poage D, Palyada K, Shrewsbury S . Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy. Int J Toxicol. 2011; 30(3):313-21. DOI: 10.1177/1091581811403505. View

Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2009; 9(1):77-93. DOI: 10.1016/S1474-4422(09)70271-6. View

Mayer O, Finkel R, Rummey C, Benton M, Glanzman A, Flickinger J . Characterization of pulmonary function in Duchenne Muscular Dystrophy. Pediatr Pulmonol. 2015; 50(5):487-94. PMC: 4402127. DOI: 10.1002/ppul.23172. View

Mazzone E, Martinelli D, Berardinelli A, Messina S, DAmico A, Vasco G . North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010; 20(11):712-6. DOI: 10.1016/j.nmd.2010.06.014. View

Wilson S, Cooke N, EDWARDS R, Spiro S . Predicted normal values for maximal respiratory pressures in caucasian adults and children. Thorax. 1984; 39(7):535-8. PMC: 459855. DOI: 10.1136/thx.39.7.535. View

Heald A, Charleston J, Iversen P, Warren T, Saoud J, Al-Ibrahim M . AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med. 2015; 373(4):339-48. DOI: 10.1056/NEJMoa1410345. View

McDonald C, Henricson E, Abresch R, Han J, Escolar D, Florence J . The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013; 48(1):32-54. PMC: 4147958. DOI: 10.1002/mus.23807. View

Kishnani P, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu W . Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2006; 68(2):99-109. DOI: 10.1212/01.wnl.0000251268.41188.04. View

10.

Mendell J, Rodino-Klapac L, Sahenk Z, Roush K, Bird L, Lowes L . Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013; 74(5):637-47. DOI: 10.1002/ana.23982. View

11.

Ciafaloni E, Fox D, Pandya S, Westfield C, Puzhankara S, Romitti P . Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009; 155(3):380-5. PMC: 5884059. DOI: 10.1016/j.jpeds.2009.02.007. View

12.

Muntoni F, Wood M . Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov. 2011; 10(8):621-37. DOI: 10.1038/nrd3459. View

13.

Mazzone E, Vasco G, Sormani M, Torrente Y, Berardinelli A, Messina S . Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology. 2011; 77(3):250-6. DOI: 10.1212/WNL.0b013e318225ab2e. View

14.

McDonald C, Henricson E, Han J, Abresch R, Nicorici A, Elfring G . The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2009; 41(4):500-10. DOI: 10.1002/mus.21544. View

15.

Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L . Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2009; 9(2):177-89. DOI: 10.1016/S1474-4422(09)70272-8. View

16.

Sazani P, Van Ness K, Weller D, Poage D, Nelson K, Shrewsbury A . Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice. Int J Toxicol. 2011; 30(3):322-33. DOI: 10.1177/1091581811403504. View

17.

van Deutekom J, Janson A, Ginjaar I, Frankhuizen W, Aartsma-Rus A, Bremmer-Bout M . Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357(26):2677-86. DOI: 10.1056/NEJMoa073108. View

18.

Kole R, Krieg A . Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev. 2015; 87:104-7. DOI: 10.1016/j.addr.2015.05.008. View

19.

Eagle M, Baudouin S, Chandler C, Giddings D, Bullock R, Bushby K . Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002; 12(10):926-9. DOI: 10.1016/s0960-8966(02)00140-2. View

20.

McDonald C, Henricson E, Abresch R, Florence J, Eagle M, Gappmaier E . The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013; 48(3):357-68. PMC: 3826053. DOI: 10.1002/mus.23905. View